The DOI matches its Crossref record; 70 of the 74 references it cites were found in a registry or an index; 14 of the 43 sources its claims cite were checked for support.
Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
Open accessAbstract
Lung cancer is the leading cause of cancer-related deaths in the world, and non-small-cell lung cancer (NSCLC) accounts for 80% of cases. MicroRNA-21 (miR-21) expression is increased and predicts poor survival in NSCLC. Although miR-21 function has been studied in vitro with cancer cell lines, the role of miR-21 in tumor development in vivo is unknown. We utilize transgenic mice with loss-of-function and gain-of-function miR-21 alleles combined with a model of NSCLC to determine the role of miR-21 in lung cancer. We show that overexpression of miR-21 enhances tumorigenesis and that genetic deletion of miR-21 partially protects against tumor formation. MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a K-rasLA2 mouse model of NSCLC, miR-21 overexpression increased lung tumor number/area and proliferation, while miR-21 deletion reduced tumor burden and sensitized transformed MEFs to doxorubicin-induced apoptosis. miR-21 acts as a tumor promoter by repressing Ras/MEK/ERK negative regulators (Spry1, Spry2, Btg2, Pdcd4) and pro-apoptotic genes (Apaf1, Faslg, Pdcd4, RhoB).
Key findings
- CAG-miR-21;K-rasLA2 mice overexpressing miR-21 4–6 fold had significantly more gross lung tumors at 18 weeks and increased microscopic tumor number and total tumor area versus K-rasLA2 littermates; tumors showed increased proliferation, but survival did not differ, possibly due to decreased thymic tumor incidence.
- miR-21−/−;K-rasLA2 mice had significantly fewer surface lung tumors at 20 weeks and decreased total tumor area; no adenocarcinomas were noted in any of 14 miR-21−/−/K-rasLA2 animals evaluated, and miR-21 deletion did not alter Ki67 proliferation.
- miR-21 overexpression alone was not sufficient for tumorigenesis: CAG-miR-21 mice without K-rasLA2 (n = 39) followed up to 555 days showed no tumors.
- Reporter assays showed 13 of 24 putative mouse miR-21 target 3′UTRs were repressed by miR-21, with mutation of the miR-21 site abrogating repression in 11; in tumors, miR-21 overexpression decreased Spry1, Spry2, Btg2, Pdcd4, Apaf1, Faslg, and RhoB and increased ERK phosphorylation. K-ras activation increased miR-21 expression 4-fold; miR-21−/− MEFs formed fewer soft agar colonies and smaller xenograft tumors and showed increased doxorubicin-induced apoptosis.
Methods
- Generated conditional CAG-miR-21 overexpressing and miR-21−/− mice, crossed to the K-rasLA2 NSCLC model; comparisons were to littermate controls, with tumor burden assessed by H&E/ImageJ, proliferation by Ki67, and apoptosis by TUNEL.
- MEFs from wild-type and miR-21−/− mice were immortalized with SV40 large T/small t and transformed with H-rasG12V; assays included soft agar, xenografts, doxorubicin treatment (100 nM–10 μM for 12 h), and TUNEL (1 μM for 12 h).
- Luciferase reporter assays tested 24 putative miR-21 target 3′UTRs; Western blots were performed on micro-dissected tumors; statistics used two-tailed unpaired Student’s t-test with p < 0.05 considered significant.
Limitations
- No formal limitations section is present; the authors state miR-21 overexpression alone was not sufficient for tumorigenesis and that tumors arising after miR-21 deletion may have developed escape mechanisms, possibly explaining latency.
- The text notes miR-21 deletion did not alter apoptosis in lung lesions, suggesting those tumors escaped miR-21 regulatory effects; no adenocarcinomas were observed in 14 miR-21−/−;K-rasLA2 animals, a limited sample for that endpoint.
- Evident from the text: all mice used were of mixed genetic backgrounds, and findings are from a mouse K-rasLA2 model and transformed MEFs, so human NSCLC causality and therapeutic implications remain to be tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 of 43 cited sources checked · 6 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Four of the validated miR-21 target genes are known negative regulators of the Ras/MEK/ERK pathway: sprouty 1 (Spry1), sprouty 2 (Spry2), B-cell translocation gene 2 (Btg2), and programmed cell death 4 (Pdcd4).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
What the sources say
- Partly supportedcites Casci et al., 1999 sourceExperimental — accuracy not yet measured
The Discussion identifies Drosophila Sprouty as an inhibitor of Ras/MAP kinase signaling. The paper predicts that mammalian Sprouty homologs may have the same function, but does not establish it for Spry1 or Spry2 specifically. It does not address Btg2, Pdcd4, or whether these genes are validated miR-21 targets. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites Hanafusa et al., 2002 source
- Not matchedcites Lo et al., 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Oncogenic Ras activation has been shown to increase the expression of Spry2, providing feedback inhibition of Ras activation (Shaw et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Partly supportedcites Shaw et al., 2007 sourceExperimental — accuracy not yet measured
In “Negative feedback signaling in development” (page not available), the paper reports that oncogenic K-ras up-regulates Spry-2 and that Spry-2 inhibits MAPK activation. It does not establish that Spry-2 inhibits activation of Ras itself; it describes possible effects at different points in the Ras/MAPK pathway, including downstream of activated K-ras. (LLM, conf=0.86)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“K-ras activation in the tumors of K-rasLA2 mice increased miR-21 expression 4-fold similar to the expression level in the CAG-miR-21 transgenic mouse lung.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total tumor area as a proportion of total lung area was significantly decreased with miR-21 deletion (Figure 2D).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 over-expression in CAG-miR-21;K-rasLA2 mutant tumors decreases Spry1, Spry2, and Btg2 protein expression compared to K-rasLA2 tumors (Figure 4C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is may be explained by a decreased incidence of thymic tumors in CAG-miR-21;K-rasLA2 mutant mice compared to K-rasLA2 controls (Figure 1I), thus contributing to the enhanced survival.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no difference in proliferation between the miR-21−/− and wild type MEFs (Figure S2C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses Ras-driven transformation In vitro
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total tumor area as a proportion of total lung area was significantly increased with miR-21 over-expression (Figure 1E).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 25
- It may state two separate claims as one. 35
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, miR-21 expression levels have proven useful prognostic markers in non-small cell lung cancer (Markou et al., 2008; Yanaihara et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Supportedcites Markou et al., 2008 source
The discussion reports that mature miR-21 overexpression in NSCLC was associated with lung-cancer death and was an independent prognostic factor in multivariate analysis. The authors caution that the small number of events requires further confirmation, so the finding should not be read as a validated clinical test. (LLM, conf=0.88)
- Partly supportedcites Yanaihara et al., 2006 sourceExperimental — accuracy not yet measured
The Results report that high hsa-mir-21 expression was associated with significantly worse survival in lung adenocarcinoma patients. They do not establish miR-21 as a validated prognostic marker across non-small cell lung cancer: the reported prognostic validation focused on other miRNAs. (LLM, conf=0.88)
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The level of miR-21 expression in sputum distinguishes NSCLC patients from cancer-free controls with a greater sensitivity than conventional cytology (Xie et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Supportedcites Xie et al., 2009 source
The Results section, under “Comparison of cytology and measurement of altered miRNA expression in sputum,” reports 69.66% sensitivity for sputum miR-21 measurement versus 47.82% for conventional sputum cytology. The study examined sputum from 23 NSCLC patients and 17 cancer-free subjects, matching the claimed comparison. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several components of the PI3K pathway, including PTEN and PIK3R1, have been suggested as miR-21 target genes (Meng et al., 2007); however, miR-21 over-expression did not alter PTEN and PIK3R1 protein expression or Akt phosphorylation (Figure S3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
What the sources say
- Partly supportedcites Meng et al., 2007 sourceExperimental — accuracy not yet measured
The Results identify PTEN as a miR-21 target, and the Discussion places PTEN in the PI3K pathway. The passages do not identify PIK3R1 as a miR-21 target. The statement that over-expression did not alter protein expression or Akt phosphorylation is attributed to the citing paper’s Figure S3B, not to Meng et al. (LLM, conf=0.87)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Targeted deletion of miR-21 in RKO and DLD1 colon cancer cells revealed miR-21 contributes to tumorigenesis through compromising cell cycle progression and DNA damage-induced checkpoint function through the Cdc25a target gene (Wang et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Partly supportedcites Wang et al., 2009 sourceExperimental — accuracy not yet measured
The Results report targeted miR-21 deletion in RKO and DLD1 cells, and the Discussion links miR-21, Cdc25A, cell-cycle progression, and checkpoint activation. However, the Discussion describes a contribution to tumorigenesis as a possibility, not a demonstrated outcome; the claim's “revealed” overstates that conclusion. (LLM, conf=0.88)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As well, epidermal growth factor receptor (EGFR) and HER2/neu signaling positively regulates miR-21 expression in human lung and breast carcinoma cell lines, respectively (Huang et al., 2009; Seike et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Supportedcites Huang et al., 2009 source
The paired citations and “respectively” attribute the HER2/neu finding in breast carcinoma cells to Huang et al. In “Ectopic Expression of HER2/neu Induces miR-21 Upregulation” (Fig. 1A; page not provided), the paper reports that HER2/neu expression increased miR-21 in a human breast cancer cell line. The EGFR finding in lung cells is not attributed to this source. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Seike et al., 2009 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Zhang et al. showed in a human gastric cancer cell line that forced over-expression of miR-21 enhanced tumor proliferation and invasion”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Supportedcites Zhang et al., 2008 source
In the Results sections on proliferation and invasion (page numbers not provided), the paper reports that transfecting AGS human gastric cancer cells with a miR-21 expression construct significantly increased proliferation and strengthened invasion. This matches the claim about forced over-expression in a human gastric cancer cell line. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SPRY2, in turn, negatively regulates Ras/MEK/ERK signaling and is a tumor suppressor in NSCLC in both mice (Minowada and Miller, 2004; Minowada and Miller, 2009; Shaw et al., 2007) and humans (Sutterluty et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Minowada and Miller, 2004 source
- Partly supportedcites Minowada and Miller, 2009 sourceExperimental — accuracy not yet measured
The study summary and Discussion (page unavailable) report fewer and smaller urethane-induced lung tumors in mice overexpressing Sprouty 2, supporting a tumor-suppressive effect in that mouse model. The Discussion says the findings are consistent with antagonism of Ras signaling, but the mechanism remains unclear; this paper does not demonstrate inhibition of MEK/ERK signaling. The citing sentence attributes the human NSCLC portion to a separate citation, not to this paper. (LLM, conf=0.83)
- Supportedcites Shaw et al., 2007 source
The Negative feedback signaling in development section reports that Spry-2 inhibits MAPK activation in K-ras G12D mouse lungs. The tumor-suppression section concludes that Spry-2 limits K-ras-driven mouse lung tumor development; a correction in Additional information says its revised results do not change that conclusion. The citing sentence attributes the human finding to Sutterluty et al., not to this paper. (LLM, conf=0.90)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All tumors from the survival cohort were analyzed on H&E sections and categorized as hyperplasia, atypical adenomatous hyperplasia, adenoma, adenoma with typia, and adenocarcinoma according to the Mouse Models of Human Cancer Consortium recommendations.(Nikitin et al., 2004)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > EXPERIMENTAL PROCEDURES > Tumor Grading
What the sources say
- Partly supportedcites Nikitin et al., 2004 sourceExperimental — accuracy not yet measured
The Development of Recommendations section says the consortium prepared and reviewed H&E-stained sections, and the classification defines hyperplasia, atypical adenomatous hyperplasia, adenoma, and adenocarcinoma. The cited paper does not identify “adenoma with typia” as a recommended category. The survival-cohort analysis describes the citing authors’ own work, not an analysis reported by Nikitin et al. (LLM, conf=0.85)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“knock-down of miR-21 resulted in a marked reduction in proliferation and increase in apoptosis (Zhang et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Supportedcites Zhang et al., 2008 source
The Abstract states that inhibiting miR-21 in AGS human gastric cancer cells significantly reduced proliferation and increased apoptosis. The ‘miR-21 Increases Cell Proliferation and Inhibits Cell Apoptosis’ section reports both effects after transfection with an anti-miR-21 inhibitor. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Partly supportedcites Hutvagner et al., 2004 sourceExperimental — accuracy not yet measured
The Results and Discussion report that 2′-O-methyl oligonucleotides inhibit specific miRNAs and can be used to study their function in C. elegans. The paper presents them as a research tool; it does not establish that they facilitate new cancer therapeutic strategies. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites Krutzfeldt et al., 2005 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RECK, Cdc25a, Map2k3, NfiB, Trp63 and Ski have been shown to be miR-21 target genes in vitro, but only RECK showed decreased protein levels in the CAG-miR-21;K-rasLA2 tumors (Figure S3A).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR21−/−;K-rasLA2 mice all develop lung tumors, but show an increased incidence of thymic lymphoma (Figure 2F).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Caspase 3 and K-ras do not contain miR-21 sites in their 3′ UTR and the 3′ UTR luciferase reporter activity is not suppressed by miR-21 (Figure 3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The decrease in Spry1, Spry2, and Btg2 in CAG-miR-21;K-rasLA2 tumors correlates with increased Ras pathway activity, shown by increased ERK phosphorylation (Figure 4C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show miR-21 dependent repression of the mouse Apaf1 3′ UTR reporter; however, the miR-21 site in the human APAF1 3′ UTR is conserved in primates but not conserved in the mouse.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“adult male CAG-miR-21 mice showed no signs of heart failure compared to littermate controls (Figure S1E)(van Rooij et al., 2006; van Rooij et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Apaf1, Pdcd4, Faslg, and RhoB were validated as direct miR-21 target genes by luciferase reporter assays; however, caspase 3 was not directly regulated by miR-21 (Figure 3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 suppresses apoptosis by targeting proapoptotic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 over-expression increased the incidence of all tumor grades without increasing the rate of conversion to adenocarcinoma, suggesting that miR-21 participates in tumor promotion rather than progression and metastasis in this model (Figure 1J and 1K).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unlike K-rasLA1;p53−/− compound mutant mice (Johnson et al., 2001), we did not observe an increased tumor spectrum or increased metastasis in the CAG-miR-21;K-rasLA2 mutant mice.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although miR-21 function has been studied in vitro using cancer cell lines, the role of miR-21 in tumor development in vivo is unknown.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A large scale survey to determine the miRNA signature of 540 tumor samples including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue revealed miR-21 was the only miRNA up-regulated in all these tumors (Volinia et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Volinia et al., 2006 source
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Further miRNA profiling in tumor samples and cancer cell lines show increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005), head and neck carcinomas (Tran et al., 2007), ovarian cancer (Iorio et al., 2007), B-cell lymphoma (Lawrie et al., 2007), hepatocellular (Meng et al., 2007), and cervical carcinoma (Lui et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“CAG-miR-21 transgenic mice were viable, fertile and born in expected Mendelian ratios.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Knock-down of miR-21 in the metastatic breast cancer MD-MBA-231 cells reduced invasion and metastasis (Zhu et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Zhu et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R. and E.N.O., manuscript in preparation).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses Ras-driven transformation In vitro
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Rests on an assumption: The miR-21 knockout mice do not have compensatory molecular changes that confound the interpretation of tumorigenesis experiments.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data illustrate that miR-21 over-expression decreases the protein expression of four miR-21 target genes that are involved in apoptosis thus promoting survival.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 suppresses apoptosis by targeting proapoptotic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
In the paper
“miR-21 expression was induced by AP-1 in response to Ras activation, and miR-21 mediated Ras-dependent downregulation of Pdcd4 (Talotta et al., 2009)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Not checked — no full text of the sourcecites Talotta et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“Knockdown of miR-21 in cultured glioblastoma cells activates caspases leading to apoptotic cell death, suggesting miR-21 is an anti-apoptotic factor (Chan et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Chan et al., 2005 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“K-rasLA2 mice develop multi-focal lung tumors with 100% penetrance, and less frequently develop thymic lymphomas and skin papillomas (Johnson et al., 2001).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
What the sources say
- Not checked — no full text of the sourcecites Johnson et al., 2001 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data suggest that miR-21 over-expression in human tumors does not simply reflect cancer pathology, but instead enhances aspects of the pathology of NSCLC.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
In the paper
“Previously, an autoregulatory loop connecting miR-21 and Ras activation through AP-1 was illustrated in a rat thyroid cell system (Talotta et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Not checked — no full text of the sourcecites Talotta et al., 2009 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data show that miR-21 over-expression decreases the protein expression of four miR-21 target genes that are tumor suppressors and negative regulators of the Ras/MEK/ERK pathway resulting in a concomitant increased ERK activity.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
In the paper
“In breast cancer MCF-7 cells, miR-21 knock-down results in suppression of cell growth in vitro and tumor growth in xenografts (Si et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not matchedcites Si et al., 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All mice used in these studies were of mixed genetic backgrounds and all comparisons were performed on littermate controls.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > EXPERIMENTAL PROCEDURES > Mouse Strains
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“PDCD4 is a pro-apoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2007; Bitomsky et al., 2008; Frankel et al., 2007; Lu et al., 2008; Zhang et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“In laryngeal carcinoma, miR-21 targets BTG2 (Liu et al., 2009), a p53 target gene, recently shown to suppress oncogenic Ras activity by reducing the GTP bound, active state (Buganim et al., 2010).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Knock-down of miR-21 in glioblastoma cell lines triggers the activation of caspases and increases apoptosis (Chan et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Chan et al., 2005 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“RhoB promotes growth inhibition and induces apoptosis in cancer cells (Kim et al., 2009)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Kim et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the reductions in protein levels of individual miR-21 targets appear modest with miR-21 over-expression, collectively this diminution of tumor suppressor activity allows for more robust tumor formation through relieving multiple nodes of inhibition of the Ras/MEK/ERK pathway, thus facilitating tumor proliferation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that Ras activation increases miR-21 expression and in turn decreasing the expression of Spry2.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“miR-21 modulates several components critical to NSCLC pathogenesis through both relieving antagonism of the Ras pathway and reducing apoptotic effectors (Figure 7).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
In the paper
“RhoB expression is down-regulated in human NSCLC suggesting a role as a tumor suppressor gene (Sato et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Sato et al., 2007 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relieving miR-21 inhibition of pro-apoptotic genes could provide a means to augment the effect of current chemotherapy.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Rests on an assumption: Apaf1, Faslg, Pdcd4 and RhoB promote apoptosis.
In the paper
“MiR-21 targets SPRY2 in cardiomyocytes and SW480 colon cancer cells, enhancing cell migration (Sayed et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Sayed et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results show that miR-21 expression modulates tumor number, incidence and size in a mouse lung cancer model initiated by oncogenic K-rasG12D, consistent with miR-21 functioning as a tumor promoter.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
In the paper
“Pdcd4 functions both as an inducer of apoptosis and a suppressor of AP-1 activity (Hwang et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Hwang et al., 2007 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Loss of PDCD4 expression in human lung cancer correlates with higher grade and disease stage (Chen et al., 2003).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Chen et al., 2003 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
“To explore the role of miR-21 in the pathogenesis of NSCLC, we utilized the K-rasLA2 murine lung cancer model, which harbors a targeted, latent K-ras G12D allele that is activated by two distinct recombination events (Johnson et al., 2001).”
The paper relies on this without support.
The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
“which globally over-expressed miR-21 4–6 fold over normal levels of expression (Figure S1B–D).”
The paper relies on this without support.
The miR-21 knockout mice do not have compensatory molecular changes that confound the interpretation of tumorigenesis experiments.
“Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R. and E.N.O., manuscript in preparation).”
The paper relies on this without support.
The antibodies used in Western blots specifically detect the intended target proteins.
“We isolated individual tumors from mice, made whole tumor lysates, and performed Western blots for putative miR-21 targets to address the effect of miR-21 expression on the protein levels of the miR-21 target genes in vivo within lung tumors.”
The paper relies on this without support.
The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
“Reporter assays in COS cells revealed miR-21 dependent repression of 13 of the 24 3′UTRs”
The paper relies on this without support.
MicroRNAs are small non-coding RNAs that are commonly dysregulated in human malignancies and play a substantial role in the pathogenesis and survival of many cancers.
“MicroRNAs are small non-coding RNAs that are commonly dysregulated in human malignancies and play a substantial role in the pathogenesis and survival of many cancers.”
The paper relies on this without support.
MiR-21 is over-expressed in the majority of human malignancies including non-small cell lung cancer (NSCLC).
“MiR-21 is over-expressed in the majority of human malignancies including non-small cell lung cancer (NSCLC).”
The paper relies on this without support.
It is not clear whether miR-21 determines important aspects of lung cancer pathogenesis or is instead simply a marker for advanced disease.
“However, it is not clear whether miR-21 determines important aspects of lung cancer pathogenesis or is instead simply a marker for advanced disease.”
The paper relies on this without support.
Spry1, Spry2, Btg2, and Pdcd4 act as negative regulators of the Ras/MEK/ERK pathway.
“which act as negative regulators of the Ras/MEK/ERK pathway”
The paper relies on this without support.
Apaf1, Faslg, Pdcd4 and RhoB promote apoptosis.
“which promote apoptosis”
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855 · cited 2×
“Expression of approximately 30% of human proteins appears to be regulated by miRNAs (Lewis et al., 2005).”
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1997 · Cited by 7,668 · cited 2×
“…including non-small-cell lung cancer (NSCLC) (Volinia et al., 2006), and are predictive of tumor classification, prognosis, and response to therapy (Calin and Croce, 2006). miRNA expression patterns are remarkably reliable markers of cancers; in some cases, they have even proven more reliable than…”
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884 · cited 4×
“MicroRNAs are evolutionarily conserved, endogenous, nonprotein-coding, 20–23 nucleotide single-stranded RNAs that negatively regulate gene expression in a sequence-specific manner (Cho, 2007; Esquela-Kerscher and Slack, 2006; Voorhoeve and Agami, 2007).”
InfluentialA microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697 · cited 4×
“A large-scale survey to determine the miRNA signature of 540 tumor samples—including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue—revealed miR-21 was the only miRNA upregulated in all these tumors (Volinia et al., 2006).”
InfluentialCombinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603 · cited 2×
“, 2007), and PicTar (Krek et al., 2005).”
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 2×
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766 · cited 2×
“Can miR-21 Targets Multiple Tumor Suppressor Genes To identify miR-21 effectors responsible for phenotypes observed, we utilized two algorithms that predict the mRNA targets of miRNAs, TargetScan (Grimson et al., 2007), and PicTar (Krek et al.”
The impact of microRNAs on protein output
Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008) · Nature · doi:10.1038/nature07242 · Cited by 3,592 · cited 2×
“Through interactions with 30 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008).”
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429 · cited 2×
“Through interactions with 30 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008).”
Flagged first, then by citations
4 of the 74 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 625
Non-coding RNAs in lung cancer
Ricciuti, B., Mecca, C., Crinò, L., Baglivo, S., Cenci, M., & Metro, G. (2014) · Oncoscience · doi:10.18632/oncoscience.98 · Cited by 38
“MiR-21 has also been found to be upregulated by KRAS in NSCLC, both in vitro and in vivo through MAPK/AP-1 activation [63-65].”
BackgroundYang, Y., Qiu, J., Kan, Q. C., et al. (2013) · Genetics and Molecular Research · doi:10.4238/2013.october.30.4 · Cited by 36
“At the molecular level, miRNAs are a class of small, non-coding, highly stable RNAs that play important and complex roles in regulating mRNA and protein expression in various physiological and pathological processes, such as cellular differentiation, proliferation, angiogenesis, metabolism, and cancer development (Car…”
BackgroundClusterin Is a Gene-Specific Target of microRNA-21 in Head and Neck Squamous Cell Carcinoma
Mydlarz, W. K., Uemura, M., Ahn, S. M., Hennessey, P., Chang, S., Demokan, S., Sun, W., Shao, C., Bishop, J. A., Krosting, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2675 · Cited by 36
“Recently, emerging evidence indicates that miRNA-21 has oncogenic properties (23, 30, 31), and inhibition of miRNA-21 could provide a new therapeutic strategy in cancer through the Ras/MEK/ERK pathway and apoptosis (33).”
Yang, P., Sun, D., & Jiang, F. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15149775533331 · Cited by 36
RetractedNi, J., Xi, X., Xiao, S., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s307595 · Cited by 36
“embedded in paraffin were subjected to immunohistochemistry with rabbit anti-HK2 antibody (ab209847, Abcam; dilution 1:500), as described elsewhere.(28)”
MethodKang, Q., Chen, B., He, M., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03234 · Cited by 36
Identification of Tumorigenic Cells in KrasG12D -Induced Lung Adenocarcinoma
Cho, H.-C., Lai, C.-Y., Shao, L., & Yu, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0903 · Cited by 36
Chen, B., Chen, X., Wu, X., Wang, X., Wang, Y., Lin, T., Kurata, J. S., Wu, J., Vonderfecht, S. L., Sun, G., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.034 · Cited by 36
“The tumorigenic role of miR-21 has been tested in mouse models where shutting down miR-21 expression inhibits growth of lymphoma and lung tumors that were induced by miR-21 over-expression [21, 42].”
BackgroundJin, X., Sun, Q., Liu, F., Yang, H., Liu, M., Liu, H., Xu, W., & Jiang, Y. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24504 · Cited by 35
“Several studies have confirmed that Sprouty1 is a target of miR-21 [Thum et al., 2008; Hatley et al., 2010].”
BackgroundMicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies
Sionov, R. V. (2013) · ISRN Hematology · doi:10.1155/2013/348212 · Cited by 35
“miR-21 overexpression potentiated lung tumorigenesis of a constitutively activated K-Ras proto-oncogene [728].”
BackgroundInvolvement of microRNAs in lung cancer biology and therapy
Liu, X., Sempere, L. F., Guo, Y., Korc, M., Kauppinen, S., Freemantle, S. J., & Dmitrovsky, E. (2011) · Translational research · doi:10.1016/j.trsl.2011.01.001 · Cited by 36
Lei, T., Zhu, Y., Jiang, C., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5370 · Cited by 35
“Increasing evidence has indicated that microRNAs (miRNAs) are deregulated in lung cancer (10-12).”
microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance
Naidu, S., & Garofalo, M. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00077 · Cited by 34
“The deletion of miR-21 in a K-rasLA2 mice (harboring latent K-ras G12D allele activated by two recombination events) model significantly reduced tumor burden, thus confirming its oncogenic role in LC (31).”
BackgroundGenetic variants in regulatory regions of microRNAs are associated with lung cancer risk
Xie, K., Wang, C., Qin, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10299 · Cited by 34
“1 promotes lung tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and apoptosis [17].”
BackgroundThe Relevance of miRNA-21 in HSV-Induced Inflammation in a Mouse Model
Choi, B., Kim, H., Suh, C., Byun, H. O., Jung, J., & Sohn, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16047413 · Cited by 36
“[54] showed that miR-21 antagomir might be therapeutically useful in preventing heart failure in mice.”
BackgroundThe Importance of microRNAs in RAS Oncogenic Activation in Human Cancer
Roncarati, R., Lupini, L., Shankaraiah, R. C., & Negrini, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00988 · Cited by 35
Shen, L., Ling, M., Li, Y., Xu, Y., Zhou, Y., Ye, J., Pang, Y., Zhao, Y., Jiang, R., Zhang, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057652 · Cited by 33
“Arsenite has effects on activation of signal pathways, such as mitogen-activated protein kinases (MAPKs), phosphoinositide-3-kinase (PI-3K)/Akt (also known as protein kinase B), and nuclear factor-kB (NF-kB) [3,4].”
BackgroundInfluentialShen, S., Mao, C.-Q., Yang, X., Du, X., Liu, Y., Zhu, Y., & Wang, J. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400714z · Cited by 34
miR-21-mediated Radioresistance Occurs via Promoting Repair of DNA Double Strand Breaks
Hu, B., Wang, X., Hu, S., Ying, X., Wang, P., Zhang, X., Wang, J., Wang, H., & Wang, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.772392 · Cited by 34
“models to show that up-regulating miR-21 promotes tumorigenesis (4-6).”
BackgroundRetractedLung tumours reprogram pulmonary dendritic cell immunogenicity at the microRNA level
Pyfferoen, L., Mestdagh, P., Vergote, K., Cabooter, N. D., Vandesompele, J., Lambrecht, B. N., & Vermaelen, K. Y. (2014) · International Journal of Cancer · doi:10.1002/ijc.28945 · Cited by 33
“Moreover, miR-21-overexpressing transgenic mice have enhanced lung tumourigenesis.(32) MiR-222 is oncogenic as well in many cancer types,(33) while much less is known about miR28 in this setting.”
BackgroundGao, W., Xu, J., & Shu, Y. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.55 · Cited by 32
Modulation of polycystic kidney disease by non-coding RNAs
Ramalingam, H., Yheskel, M., & Patel, V. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109548 · Cited by 34
“With regards to diseases, miR-21 is activated in multiple types of cancers including glioblastoma, chronic lymphocytic leukemia, lymphoma and lung cancer, where it functions as a pro-survival, anti-apoptotic oncogenic miRNA (41, 47, 48).”
BackgroundGuo, L., Xu, K., Yan, H., Feng, H., Wang, T., Chai, L., & Xu, G. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6104 · Cited by 32
“Liu et al (30) reported that miR-21 promoted collagen deposition by targeting SMAD family member 7, whilst Hatley et al (31) reported that miR-21 drove tumorigenesis through inhibition of negative regulators of the Ras/MEK/extracellular signal-regulated kinase pathway.”
MicroRNA and MET in lung cancer.
Brighenti, M. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.01.26 · Cited by 31
“Another oncoMir regulated by both EGFR and MET is miR-21; data from transgenic tumor models show that it drives tumorigenesis by repressing negative regulators of the Ras/MEK/ERK, Ras/PI3K/Akt and Ras/RalGDS/JNK pathways (61); when it is overexpressed it represses PTEN inducing gefitinib resistance (62), while its blo…”
BackgroundExosomal miRs in Lung Cancer: A Mathematical Model
Lai, X., & Friedman, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167706 · Cited by 34
Saini, V., Dawar, R., Suneja, S., Gangopadhyay, S., & Kaur, C. (2021) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00125-w · Cited by 32
miRNA expression profiles associated with diagnosis and prognosis in lung cancer
Jiang, C., Hu, X., Alattar, M., & Zhao, H. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.870037 · Cited by 31
MicroRNAs: Modulators of theRasOncogenes in Oral Cancer
Murugan, A. K., Munirajan, A. K., & Alzahrani, A. S. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25269 · Cited by 32
“Moreover, aberrant Kras activation is well demonstrated in human cancers with significantly higher prevalence of Kras mutations in NSCLC.”
BackgroundInfluentialLiang, T., Hu, X., Li, Y., Tian, B., Li, Z., & Fu, Q. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14685034103356 · Cited by 31
“(20) have showed that incidence of lung tumors is significantly high in miRNA-21-overexpressing mice (20).”
BackgroundKeshavarzmotamed, A., Mousavi, V., Masihipour, N., Rahmati, A., Dehmordi, R. M., Ghezelbash, B., Alimohammadi, M., & Mafi, A. (2023) · Current Molecular Pharmacology · doi:10.2174/0118761429249717230920113227 · Cited by 32
Nielsen, B. S., Balslev, E., Poulsen, T. S., Nielsen, D. L., Møller, T., Mortensen, C. E., Holmstrøm, K., & Høgdall, E. V. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00207 · Cited by 31
“In a K-ras-dependent lung cancer model, overexpression of miR-21 caused increased tumor formation, whereas miR-21 deficiency reduced the tumor formation (41).”
BackgroundLiang, L.-H., & He, X. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.103 · Cited by 30
Tang, S., Bonaroti, J. W., Unlu, S., Liang, X., Tang, D., Zeh, H. J., & Lotze, M. T. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182854ab0 · Cited by 30
Yu, Y., Chen, Z., Liu, H., Jin, W., Ding, Z., & Zheng, S. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s103893 · Cited by 30
“37 Additionally, previous studies reported that many tumor suppressors have been experimentally verified as the targets of miR-21 in CRC and other cancers, such as PTEN, 38,39 ITG β 4, and PDCD4.”
Liu, Z., Li, C., Chen, S., Lin, H., Zhao, H., Liu, M., Weng, J., Liu, T., Liu, T., Lei, C., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27742 · Cited by 30
Xu, S., Wang, G., Feng, Y., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05839 · Cited by 29
Pseudorabies viral replication is inhibited by a novel target of miR-21
Huang, J., Ma, G., Fu, L., Jia, H., Zhu, M., Li, X., & Zhao, S. (2014) · Virology · doi:10.1016/j.virol.2014.03.032 · Cited by 29
microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance
Zhang, W. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236094 · Cited by 29
“Activating KRAS mutations confer both primary [205] and acquired [206] resistance to anti-EGFR cetuximab therapy in colorectal cancer.”
BackgroundInfluentialFlavonoid display ability to target microRNAs in cancer pathogenesis
Singh, S., Raza, W., Parveen, S., Meena, A., & Luqman, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114409 · Cited by 30
MiR-130a-3p suppresses colorectal cancer growth by targeting Wnt Family Member 1 (WNT1)
Song, G.-L., Xiao, M., Wan, X., et al. (2021) · Bioengineered · doi:10.1080/21655979.2021.1977556 · Cited by 29
Silva, G. P. D. L., & Aboussekhra, A. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22299 · Cited by 31
The Type I IFN-Induced miRNA, miR-21
Yang, C. H., Li, K., Pfeffer, S. R., & Pfeffer, L. M. (2015) · Pharmaceuticals · doi:10.3390/ph8040836 · Cited by 29
Over-Expression of miR-21 and Lower PTEN Levels in Wilms’ Tumor with Aggressive Behavior
Cui, M., Liu, W., Zhang, L., Guo, F., Liu, Y., Chen, F., Liu, T., Ma, R., & Wu, R. (2017) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.242.43 · Cited by 28
“Hatley et al. (2010) reported that PTEN is not a target gene of miR-21 in NSCLC. Cheng et al. (2005) reported that inhibiting miR21 in HeLa cells could significantly accelerate cell growth.”
BackgroundmiR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Jin, H., Li, Q., Cao, F., Wang, S., Wang, R.-T., Wang, Y., Tan, Q.-Y., Li, C.-R., Zou, H., Wang, D., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.09.005 · Cited by 28
“Evidence has shown that the expression of miRNAs is dysregulated in most cancers, and the dysregulation of certain miRNAs plays a key role in cancer progression by activating oncogenic signaling pathways, including the Akt pathway.(14,15) Specifically, downregulated miR-124 expression was identified in several types o…”
BackgroundWang, L., Wang, T., Gu, J.-Q., & Su, H. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171672 · Cited by 28
“Research has shown that miR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.(19) Garofalo et al(20) reported that additional targets of miRNAs 221, such as PETN/TIMP3(21) and PUMA (also known as Bcl-2 binding component 3),(22) seem to mediate TRA…”
Zhang, F., & Cao, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4655 · Cited by 28
“A previous study demonstrated that miR‑21 increased the activation of oncogenic k‑Ras and modulated non‑small‑cell lung cancer tumorigenesis via suppressing the negative regulators of the Ras/Raf/MEK/ERK pathway (25).”
Zeinali, F., Zarch, S. M. A., Mehrjardi, M. Y. V., Kalantar, S. M., Jahan-Mihan, A., Karimi‐Nazari, E., Fallahzadeh, H., Hosseinzadeh, M., Rahmanian, M., Fazeli, M. R., et al. (2020) · Trials · doi:10.1186/s13063-020-04236-y · Cited by 31
Papadaki, C., Monastirioti, A. A., Rounis, K., Makrakis, D., Kalbakis, K., Nikolaou, C., Mavroudis, D., & Agelaki, S. (2020) · Cancers · doi:10.3390/cancers12051282 · Cited by 29
“MiR-21 has been also associated with resistance of NSCLC cells to cisplatin through phosphatase and tensin homolog (PTEN) targeting and inhibition of apoptosis [17], whereas its deletion sensitized cells to DNA-damaging chemotherapy [18].”
BackgroundThe Versatile Role of miR-21 in Renal Homeostasis and Diseases
Larrue, R., Fellah, S., der Hauwaert, C. V., Hennino, M.-F., Perrais, M., Lionet, A., Glowacki, F., Pottier, N., & Cauffiez, C. (2022) · Cells · doi:10.3390/cells11213525 · Cited by 28
Emerging roles of noncoding RNAs in human cancers
Wu, S., Wu, Y., Deng, S., Lei, X., & Yang, X. (2023) · Discover Oncology · doi:10.1007/s12672-023-00728-w · Cited by 30
“A study indicates miR-21 overexpression induces pre-B-cell lymphoma in mice [80, 81], promoting KRAS-dependent carcinogenesis by activating the Ras/MEK/ERK pathway [82].”
BackgroundZhang, H., Li, P., Ju, H., Pešta, M., Kulda, V., Jin, W., Cai, M., Liu, C., Wu, H., Xu, J., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0598 · Cited by 28
“Besides, miR21 has been reported to play an important role in suppressing proapoptotic genes and modulating the vital components of the Ras/MEK/ERK pathway (45).”
BackgroundmiR-346 Promotes HCC Progression by Suppressing Breast Cancer Metastasis Suppressor 1 Expression
Guo, Z., Li, J., Sun, J., et al. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x15145088802439 · Cited by 27
Peng, Y., Li, J., & Zhu, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816843-1.00008-4 · Cited by 27
Go, R., Kim, C., & Choi, K. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.09.001 · Cited by 27
miR-24-mediated knockdown of H2AX damages mitochondria and the insulin signaling pathway
Jeong, J. H., Kang, Y. C., Piao, Y., Kang, S., & Pak, Y. K. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.174 · Cited by 27
Sheervalilou, R., Shirvaliloo, S., Aval, S. F., Khamaneh, A. M., Sharifi, A., Ansarin, K., & Zarghami, N. (2017) · Tumor Biology · doi:10.1177/1010428317695032 · Cited by 27
Mehta, A. K., Hua, K. L., Whipple, W. J., Nguyen, M.-T., Liu, C., Haybaeck, J., Weidhaas, J. B., Settleman, J., & Singh, A. (2017) · Science Signaling · doi:10.1126/scisignal.aam6291 · Cited by 28
“In some cases, the function of miRNAs can be oncogenic, as highlighted by the role of miR-21 in KRAS-driven lung cancer progression (10).”
BackgroundAbuduhier, F. M., Javid, J., Sughayer, M. A., et al. (2018) · PubMed · doi:10.22034/apjcp.2018.19.9.2607 · Cited by 27
“…et al., 2006). miRNA-21 targets Spry2, BTG2 and PDCD4 thereby enhances oncogenic K-ras activation and modulates tumorigenesis in lung cancer (Hatley et al., 2010). miR-21 also targets PTEN, RECK, and Bcl-2 in lung squamous cell carcinoma that regulates cell proliferation, apoptosis, and…”
BackgroundPlatelet miRNAs and cardiovascular diseases
Eduardo Fuentes, Q., Palomo, I. F., & Alarcón, M. A. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.04.016 · Cited by 29
Kim, E. H., Choi, J., Jang, H., Kim, Y., Lee, J. W., Ryu, Y., Choi, J., Choi, Y., Chi, S.-G., Kwon, I. C., et al. (2024) · Theranostics · doi:10.7150/thno.97755 · Cited by 30
“Furthermore, miR-21, a crucial oncogene in cancer treatment, inhibits the negative regulators of RAS/MEK/ERK signaling by suppressing the expression of PDCD4 and SPRY2 [27, 28].”
BackgroundLima, R. Q. D. S., Vasconcelos, C. F. M., Gomes, J. P. A., de Menezes, E. D. S. B., Silva, B. D. O., Montenegro, C., Júnior, S. D. S. L. P., & Pereira, M. C. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155601 · Cited by 26
MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer
Mirahmadi, Y., Nabavi, R., Taheri, F., Samadian, M. M., Ghale-Noie, Z. N., Farjami, M., Samadi-khouzani, A., Yousefi, M., Azhdari, S., Salmaninejad, A., et al. (2021) · Journal of Oncology · doi:10.1155/2021/3408937 · Cited by 29
“Furthermore, miR-21 is able to lead tumorigenesis by preventing the negative regulators like Ras/MEK/Erk pathway [110].”
BackgroundThe Effect of miRNA Gene Regulation on HIV Disease
Chinniah, R., Adimulam, T., Nandlal, L., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.862642 · Cited by 26
“Significant success has been observed in several clinical trials using potential miRNA drugs in multiple infectious and non-infectious diseases, including cancer (Hatley et al., 2010; Li et al., 2010; Steele et al., 2011; Wong et al., 2012; Yamanaka et al., 2012), hepatitis C (Jopling et al.”
BackgroundCRISPR/Cas‐Based MicroRNA Biosensors
Zhang, Q., Zhang, X., Zou, X., Ma, F., & Zhang, C. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202203412 · Cited by 26
Glass Nanopipette-Based Plasmonic SERS Platform for Single-Cell MicroRNA-21 Sensing during Apoptosis
Wang, Y., Wang, D., Qi, G., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03042 · Cited by 26
Sudhir, P., Chen, C., Kumari, M. P., Wang, M.-J., Tsou, C., Sung, T., Chen, C., & Chen, C. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.020875 · Cited by 26
“Similar results have been observed with PDCD4 down-regulation in mouse model of nonsmall cell lung cancer (35).”
The miRNA network: micro-regulator of cell signaling in cancer
Mei, Q., Li, X., Guo, M., Fu, X., & Han, W. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.953935 · Cited by 26
“miR-21 Oncogene PDCD4, PTEN, PI3K/AKT, Ras/MEK/ERK pathway CLL, NSCLC, Breast, Lung, Colon cancer [133–137]”
MiR-21 and let-7 cooperation in the regulation of lung cancer
Bai, J., Shi, Z., Wang, S., Pan, H. B., & Zhang, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950043 · Cited by 25
“Previous research has concentrated on treating lung cancer by regulating a negative regulatory target gene mRNA, a pathway involving miRNA (6); however, some miRNAs can also indirectly positively regulate mRNA by regulating other cytokines (7).”
BackgroundOncomiR detection in circulating body fluids: a PDMS microdevice perspective
Potrich, C., Vaghi, V., Lunelli, L., Pasquardini, L., Santini, G., Ottone, C., Quaglio, M., Cocuzza, M., Pirri, C. F., Ferracin, M., et al. (2014) · Lab on a Chip · doi:10.1039/c4lc00630e · Cited by 26
Ram, R. R., Mendiratta, S., Bodemann, B. O., Torres, M. J., Eskiocak, U., & White, M. A. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01506-13 · Cited by 25
“The latter has stimulated much interest in development of strategies for miR-21 inhibition as a therapeutic intervention (25, 39).”
BackgroundTyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Santarpía, M., Altavilla, G., Salazar, M., Magrí, I., Pettineo, G., Benecchi, S., & Rosell, R. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.27 · Cited by 24
Jiang, M., Li, X., Quan, X., Li, X., & Zhou, B. (2018) · BioMed Research International · doi:10.1155/2018/5930951 · Cited by 24
“Upregulation of miR-21 could promote the tumorigenesis of lung cancer through inhibiting the apoptosis process and negatively regulating the Ras/MEK/ERK signal pathway [9].”
miR-31 Displays Subtype Specificity in Lung Cancer
Davenport, M. L., Echols, J. B., Silva, A. D., Anderson, J. C., Owens, P., Yates, C. C., Wei, Q., Harada, S., Hurst, D. R., & Edmonds, M. D. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2769 · Cited by 26
“One class of noncoding genes that has seen significant investigation aremiRNAs, which have broadly been reported as having dysregulated expression in lung cancer, with many having tumor suppressive or oncogenic properties within lung cancer such as let-7 and miR-34 or miR-21, respectively (15, 16).”
BackgroundGrzes, M., Oroń, M., Staszczak, Z., Jaiswar, A., Nowak-Niezgoda, M., & Walerych, D. (2020) · Cancers · doi:10.3390/cancers12061532 · Cited by 24
miR-21 coordinates tumor growth and modulates KRIT1 levels
Orso, F., Balzac, F., Marino, M., Lembo, A., Retta, S. F., & Taverna, D. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.031 · Cited by 25
MiR-21 Is under Control of STAT5 but Is Dispensable for Mammary Development and Lactation
Feuermann, Y., Kang, K., Shamay, A., Robinson, G. W., & Hennighausen, L. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085123 · Cited by 25
“Generation of miR-21 mice was previously described [22].”
MethodSprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL
Shukla, A., Rai, K., Shukla, V., Chaturvedi, N. K., Bociek, R. G., Pirruccello, S. J., Band, H., Lu, R., & Joshi, S. S. (2016) · Blood · doi:10.1182/blood-2015-09-669317 · Cited by 24
“High miR-21 expression has been shown to activate MAPK-Erk signaling in several malignancies by suppressing SPRY2 levels.(33,41) However, in this report, we have shown the molecular mechanism through which miR-21 leads to disease advancement.”
BackgroundFeng, Y., Ma, J., Xiang, R., & Li, X. (2017) · Toxicon · doi:10.1016/j.toxicon.2017.01.016 · Cited by 24
“Currently, an increasing number of studies have proven that miR-21 is an onco-microRNA and it was found to be upregulated in virtually all types of cancers and various types of hematological malignancies (Krichevsky and Gabriely, 2009; Hatley et al., 2010; Liu et al., 2010, 2011; Ma et al., 2011).”
BackgroundTriantaphyllopoulos, K. A., Ragia, N. D., Panagiotopoulou, M.-C. E., & Sourlingas, T. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199498 · Cited by 30
Regulatory Non-coding RNAs in Atherosclerosis
Schober, A., Maleki, S. S., & Nazari-Jahantigh, M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_423 · Cited by 25
Langdon, C. G., Gadek, K. E., Garcia, M. R., Evans, M. K., Reed, K. B., Bush, M., Hanna, J. A., Drummond, C. J., Maguire, M. C., Leavey, P. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25829-4 · Cited by 25
Self-citationFan, D., Yang, Y., & Zhang, W. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01731-z · Cited by 24
“The tumors embedded in paraffin were subjected to immunohistochemistry assays using rabbit anti-TGFBR2 antibody (PA5-88257; dilution 1:100) from Invitrogen and rabbit anti-Ki67 antibody (ab16667; dilution 1:200) from Abcam, as described elsewhere [19].”
MethodThe diverse roles of miRNAs in HIV pathogenesis: Current understanding and future perspectives
Rashid, F., Zaongo, S. D., Song, F., & Chen, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1091543 · Cited by 23
Connecting the dots in the associations between diet, obesity, cancer, and microRNAs
Otsuka, K., Nishiyama, H., Kuriki, D., Kawada, N., & Ochiya, T. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.001 · Cited by 26
Molecular Biology and Clinical Management of Esophageal Adenocarcinoma
Li, S., Hoefnagel, S. J. M., & Krishnadath, K. K. (2023) · Cancers · doi:10.3390/cancers15225410 · Cited by 23
“Moreover, miR-21 is overexpressed in EAC and is thought to play a role in the initiation and development of EAC by disrupting apoptosis due to activation of Ras/MEK/ERK signaling and NF-κ B signaling [155,158–160].”
BackgroundMiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis
Yang, C. H., Wang, Y., Sims, M. M., Cai, C., He, P., Yue, J., Cheng, J., Boop, F. A., Pfeffer, S. R., & Pfeffer, L. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12401 · Cited by 22
“For example, miR21 is frequently overexpressed in various human tumors and silences the expression of tumor suppressors; miR21 plays an important role in the oncogenic process and is associated with high proliferation, low apoptosis, high invasion and metastatic potential [24-33].”
BackgroundmiR-21: a promising biomarker for the early detection of colon cancer
Dehghan, F., Boozarpour, S., Torabizadeh, Z., & Alijanpour, S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s199508 · Cited by 23
MicroRNA Sensors Based on CRISPR/Cas12a Technologies: Evolution From Indirect to Direct Detection
Yu, S., Lei, X., & Qu, C. (2024) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2024.2329229 · Cited by 22
“[9] In contrast, miRNA-34a has been identified as a tumor suppressor in lung cancer and may be regarded as a potential therapeutic target.”
Safe, S. H. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-014-0012-8 · Cited by 22
Kunz, M., Göttlich, C., Walles, T., Nietzer, S., Dandekar, G., & Dandekar, T. (2017) · Tumor Biology · doi:10.1177/1010428317706430 · Cited by 23
Polyphenols as Lung Cancer Chemopreventive Agents by Targeting microRNAs
Li, J., Zhong, X., Zhao, Y., Shen, J., Pilapong, C., & Xiao, Z. (2022) · Molecules · doi:10.3390/molecules27185903 · Cited by 22
Prognostic Role of MicroRNA-21 in Non-small Cell Lung Cancer: a Meta-analysis
Ma, X., Liu, L., Liu, X., Li, Y., Deng, L., Xiao, Z., Liu, Y., Shi, H., & Wei, Y.-Q. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.5.2329 · Cited by 22
“As referred in Hayes (Hayes et al. 2001), a prognostic factor with RR>2 is considered as useful practical value.”
BackgroundXu, L., Xu, L., Zhou, X. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073762 · Cited by 22
Nagarajan, M. B., Tentori, A. M., Zhang, W. C., Slack, F. J., & Doyle, P. S. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b02010 · Cited by 22
Bonci, D., & Maria, R. D. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1109744 · Cited by 22
Thromboxane A2 receptor α promotes tumor growth through an autoregulatory feedback pathway
Huang, R.-Y., Li, M.-Y., Ng, C. S. H., et al. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt038 · Cited by 21
“Interestingly, PTEN is downregulated in a progressive smoking-dependent manner in smokers with chronic obstructive pulmonary disease, one of major risks for lung cancer (Shaykhiev et al., 2011).”
BackgroundInfluentialFrom Endogenous to Synthetic microRNA-Mediated Regulatory Circuits: An Overview
Ferro, E., Bena, C. E., Grigolon, S., & Bosia, C. (2019) · Cells · doi:10.3390/cells8121540 · Cited by 23
MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer
Pan, H., Pan, Z., Guo, F., Meng, F., Zu, L., Fan, Y., Li, Y., Li, M., Du, X., Zhang, X., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08961-8 · Cited by 21
“For instance, miR-21, acting as an oncogene, suppressed cell apoptosis and promoted NSCLC tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway in vitro and in vivo [11].”
BackgroundEsmaeilzadeh, A. A., Yaseen, M. M., Rabbimovich, K. U., Al-Gazally, M. E., Opulencia, M. J. C., Jalil, A. T., & Mohammed, R. N. (2022) · Analytical Methods · doi:10.1039/d2ay01384c · Cited by 22
Go, R., Kim, C., Jeon, S., Byun, Y., Jeung, E., Nam, K., & Choi, K. (2016) · Environmental Toxicology · doi:10.1002/tox.22337 · Cited by 21
“, 2013), and regulates invasion and metastasis by tumor repressors via stimulation of microRNA-21 (miR-21) expression through ER in breast cancer cells (Wickramasinghe et al., 2009; Hatley et al., 2010; Teng et al., 2013).”
Background
Metadata
- Authors
- Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., & Olson, E. N.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Olson, Eric N.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 18
- Issue
- 3
- Pages
- 282-293
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2971666
- OpenAlex
- W2169354377
- Semantic Scholar
- ea1aaa83b1883a1290ce31db3401b12568b668c7
- Cited by
- 626
- References
- 74
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 22 · 2022: 38 · 2021: 31 · 2020: 28 · 2019: 29 · 2018: 42 · 2017: 31 · 2016: 40 · 2015: 72 · 2014: 57 · 2013: 62 · 2012: 63
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL093039)
- National Cancer Institute
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD000850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-21, KRAS, lung carcinogenesis, non-small cell lung cancer, Ras/MEK/ERK pathway, apoptosis inhibition, transgenic mouse model, tumor suppressor microRNA
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Cell Transformation, Neoplastic, Humans, Lung Neoplasms, Mice, Nude, Mice, Transgenic, Genes, ras, Signal Transduction, MicroRNAs, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review